New York Times Updates Article on AI Startup Medvi After Reader Criticism Over Omissions

The New York Times has issued a substantial update to a recent profile of Medvi, an AI-powered marketing platform for telehealth providers and compounding pharmacies, after readers pointed out critical omissions in the original article.

NYT’s Initial Profile of Medvi

The original New York Times piece, published last week, framed Medvi as an AI-driven success story. The startup, helmed by a single founder and operated with a minimal team, was described as on track to surpass $1 billion in sales. The article portrayed Medvi’s rapid growth as a testament to the power of AI in modern marketing.

Reader Criticism Reveals Key Omissions

Readers quickly identified several critical details missing from the NYT’s profile, including:

• A warning letter from the FDA regarding alleged regulatory violations, specifically related to "false and misleading" marketing content.
• Multiple legal actions, including an ongoing class action lawsuit accusing Medvi of violating California’s spam laws.
• Allegations of deceptive marketing tactics, such as falsely claiming partnerships with doctors and manipulating "before-and-after" patient photos using images of random individuals.

These issues were first reported by Futurism in May 2025.

NYT Issues Correction and Updates Article

In response to the criticism, the New York Times appended an editor’s note to the article, acknowledging the omissions and updating the piece to include:

"After this article was published, many readers noted that Medvi was facing legal and regulatory actions for its business practices. Our piece should have included that information to give readers a fuller picture of the scrutiny that the company was facing. We have updated the article to note a warning letter from the FDA and a pending class action lawsuit accusing Medvi of violating California’s anti-spam law."

The update also included a tweet from Rob Freund, a legal expert, who criticized the NYT for failing to conduct basic due diligence on the company:

"We should have done the barest Googling of the business we wrote about." — Rob Freund (@RobertFreundLaw), April 10, 2026

Medvi Responds to Scrutiny

In a statement released amid the growing scrutiny, Medvi largely attributed its challenges to the actions of "uncouth affiliate marketers." The company did not address specific allegations regarding compliance failures or deceptive marketing practices in its response.

For further details on the fallout, see Futurism’s coverage: AI-Powered Drug Marketer Medvi Responds After Allegations About Fake Doctors and Patients.